Livraghi T, Bolondi L, Buscarini L, Cottone M, Mazziotti A, Morabito A, Torzilli G
Serv. Radiologia, Hospital of Vimercate, Milano, Italy.
J Hepatol. 1995 May;22(5):522-6. doi: 10.1016/0168-8278(95)80445-5.
BACKGROUND/AIMS: This retrospective study was undertaken to obtain information relevant to the therapeutic strategy in single hepatocellular carcinoma associated with Child's A and B cirrhosis.
From a total of 1108 consecutive patients with hepatocellular carcinoma, 391 patients with single, small (< or = 5 cm) hepatocellular carcinoma (260 in Child A class and 131 in Child B class) were observed: 120 were treated by surgical resection, 155 by percutaneous ethanol injection and 116 were untreated. The end point of the study was 3-year survival. The log rank test was used to compare survival among the different groups.
In the Child A group the cumulative 3-year survival was 79% for surgery, 71% for percutaneous ethanol injection and 26% for no treatment (p < 0.001 for surgery versus no treatment, p < 0.001 for percutaneous ethanol injection vs no treatment). In patients comparable to the surgical group, i.e. potentially operable, survival was 80% for percutaneous ethanol injection and 30% for no treatment. In the Child B group the 3-year survival was 40% for surgery, 41% for percutaneous ethanol injection and 13% for no treatment (p < 0.01 for surgery vs no treatment and p < 0.001 for percutaneous ethanol injection vs no treatment).
Surgery and percutaneous ethanol injection improve survival in single hepatocellular carcinoma associated with Child A and B cirrhosis compared to untreated patients in the same Child class. A controlled study to identify factors affecting the choice of treatment is justified.
背景/目的:本回顾性研究旨在获取与Child A级和B级肝硬化合并单发性肝细胞癌治疗策略相关的信息。
在总共1108例连续性肝细胞癌患者中,观察了391例单发性小(≤5 cm)肝细胞癌患者(Child A级260例,Child B级131例):120例接受手术切除治疗,155例接受经皮乙醇注射治疗,116例未接受治疗。研究终点为3年生存率。采用对数秩检验比较不同组之间的生存率。
在Child A组中,手术组3年累积生存率为79%,经皮乙醇注射组为71%,未治疗组为26%(手术组与未治疗组相比,p<0.001;经皮乙醇注射组与未治疗组相比,p<0.001)。在与手术组情况相当(即有可能进行手术)的患者中,经皮乙醇注射组生存率为80%,未治疗组为30%。在Child B组中,手术组3年生存率为40%,经皮乙醇注射组为41%,未治疗组为13%(手术组与未治疗组相比,p<0.01;经皮乙醇注射组与未治疗组相比,p<0.001)。
与同一Child分级中未接受治疗的患者相比,手术和经皮乙醇注射可提高Child A级和B级肝硬化合并单发性肝细胞癌患者的生存率。开展一项对照研究以确定影响治疗选择的因素是合理的。